D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala

This article summarizes several clinical trials investigating the use of OSE2101 (TEDOPI), an innovative cancer vaccine, in treating various advanced cancers. OSE2101 contains multiple synthetic peptides designed to stimulate the immune system to target cancer cells. The trials are evaluating OSE2101 alone or in combination with other therapies for cancers including non-small cell lung cancer, ovarian cancer, and pancreatic cancer. These studies aim to assess the safety and efficacy of OSE2101 in improving outcomes for patients with difficult-to-treat advanced cancers.

Related diseases and areas:

• Squamous cell carcinoma of …
• Ductal adenocarcinoma of pa…
• Non-small cell lung cancer …
• Non-small cell lung cancer
• Ovarian cancer
• Non-small cell lung cancer …

D-Camphor

This article discusses a clinical trial investigating the use of Aconite Pain Oil, which contains D-Camphor as one of its active ingredients, in cancer patients undergoing chemotherapy. The study aims to prevent and reduce symptoms of chemotherapy-induced polyneuropathy (CIPN) and improve patients’ quality of life. The trial is designed to compare the effectiveness of the Aconite Pain Oil against a placebo in managing CIPN symptoms and potentially reducing the risk of developing severe CIPN.

Related diseases and areas:

• Polyneuropathy

D-Prolyl-D-Threonyl-D-Leucyl-D-Histidyl-D-Threonyl-D-Histidyl-D-Asparaginyl-D-Arginyl-D-Arginyl-D-Arginyl-D-Arginyl-D-Arginine Amide Acetate

A clinical trial is underway to evaluate the safety and effectiveness of a new drug called PRI-002 for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD). This study aims to assess how well the drug works and if it’s safe to use in people with early stages of Alzheimer’s. The trial is designed to be randomized, double-blind, and placebo-controlled, which means participants will be randomly assigned to receive either PRI-002 or a placebo, and neither the patients nor the researchers will know who is receiving the actual drug during the study.

Related diseases and areas:

• Dementia Alzheimer’s type

D,L-Lysine Acetylsalicylate

This article discusses a clinical trial investigating the use of intravenous D,L-Lysine Acetylsalicylate (Aspirin) in patients with Acute Coronary Syndrome (ACS). The study compares the effectiveness of different doses and administration methods of Aspirin in treating ACS, focusing on its impact on various biological markers and clinical outcomes.

Related diseases and areas:

• Colorectal cancer metastatic
• Chronic coronary syndrome
• Angiopathy
• Ischaemic stroke
• Immune thrombocytopenia
• Arteriosclerosis

D5-Ethyl-Beta-D-Glucuronide

A new clinical trial is underway to assess the effectiveness of a breath-based diagnostic test for lung cancer using D5-Ethyl-Beta-D-Glucuronide. This study, known as the OWL-EVO1 Breath Biopsy test, aims to differentiate between individuals with lung cancer and those without, potentially offering a less invasive alternative to current diagnostic methods. The trial will evaluate the test’s accuracy, optimize its parameters, and assess the safety and tolerability of the compound used.

Related diseases and areas:

• Adenosquamous cell lung cancer
• Adenosquamous cell lung can…
• Large cell lung cancer stage 0
• Adenosquamous cell lung can…
• Large cell lung cancer
• Adenosquamous cell lung can…

Dabigatran

This article examines the use of dabigatran, a blood-thinning medication, in clinical trials for various medical conditions. Dabigatran, also known by its brand name Pradaxa, has been studied for its effectiveness in preventing blood clots and reducing the risk of stroke in patients with atrial fibrillation. We’ll explore the key findings from several clinical trials, focusing on the drug’s safety profile, dosing regimens, and potential interactions with other medications.

Related diseases and areas:

• Embolism venous
• Chronic coronary syndrome
• Atrial fibrillation
• Cerebrovascular accident
• Haemorrhage
• Atrial flutter

Dabigatran Etexilate

Dabigatran etexilate, also known by the brand name Pradaxa, is an anticoagulant medication that has been the subject of numerous clinical trials. These studies aim to evaluate its safety and effectiveness in preventing blood clots and reducing the risk of stroke in patients with various conditions, including atrial fibrillation, kidney disease, and after knee replacement surgery. The trials explore different dosages, compare dabigatran to other anticoagulants like warfarin, and assess its impact on kidney function and bleeding risks.

Related diseases and areas:

• Cardiac ventricular thrombosis
• Ischaemic stroke
• Pulmonary hypertension
• Acute myocardial infarction
• Atrial fibrillation

Dabrafenib Mesylate

This article summarizes several clinical trials investigating the use of dabrafenib mesylate, often in combination with other drugs, for treating various types of cancer. Dabrafenib mesylate is a targeted therapy that inhibits the BRAF protein, which is involved in cell growth and division. These trials aim to evaluate the safety and effectiveness of dabrafenib-based treatments for cancers with specific genetic mutations, particularly BRAF mutations.

Related diseases and areas:

• Metastatic malignant melanoma
• Neoplasm malignant
• Non-small cell lung cancer
• Neoplasm

Dacarbazine Citrate

Dacarbazine Citrate is a chemotherapy medication being studied in clinical trials for various types of cancer, particularly melanoma and Hodgkin lymphoma. This article explores the use of Dacarbazine Citrate in ongoing clinical trials, its potential benefits, and what patients should know about participating in these studies.

Related diseases and areas:

• Ocular melanoma
• Malignant melanoma
• Soft tissue sarcoma
• Uveal melanoma
• Hodgkin’s disease

Dacomitinib

Dacomitinib is an oral medication being studied in clinical trials for various types of cancer, particularly non-small cell lung cancer (NSCLC). As a pan-HER inhibitor, it targets multiple proteins involved in cancer growth. This article summarizes key findings from clinical trials investigating dacomitinib’s safety, efficacy, and pharmacokinetics in different patient populations.

Related diseases and areas:

• Plasma cell myeloma
• Non-small cell lung cancer
• Non-Hodgkin’s lymphoma
• Neoplasm malignant

Dactinomycin

Dactinomycin, also known as Actinomycin D, is an important chemotherapy drug being studied in various clinical trials for the treatment of different types of cancer. This article explores recent research on dactinomycin’s use in combination therapies and its potential benefits for patients with conditions like gestational trophoblastic neoplasia, rhabdomyosarcoma, and other rare cancers.

Related diseases and areas:

• Rhabdomyosarcoma
• Nephroblastoma
• Atypical teratoid/rhabdoid …
• Neoplasm malignant
• Gastroenteropancreatic neur…

Dactylis Glomerata Pollen Extract, Enriched

This article discusses a clinical trial investigating the use of Dactylis Glomerata Pollen Extract, Enriched, for diagnosing allergies. The study aims to determine the effectiveness of this extract in skin prick tests and assess its safety for patients with allergies to Dactylis glomerata (orchard grass) pollen.

Dalbavancin

Dalbavancin is an innovative antibiotic being studied in clinical trials for treating various bacterial infections. This long-acting medication shows potential for reducing hospital stays and improving patient outcomes across different types of infections. The following article summarizes key findings from recent clinical trials investigating dalbavancin’s effectiveness and safety.

Related diseases and areas:

• Endocarditis enterococcal
• Haematological infection
• Staphylococcal infection

Danicamtiv

Danicamtiv, also known as BMS-986434 or MYK-491, is a novel drug currently being studied in clinical trials for various heart conditions, including dilated cardiomyopathy and heart failure with reduced ejection fraction. This article provides an overview of the ongoing research, potential benefits, and safety considerations of Danicamtiv based on recent clinical trials.

Related diseases and areas:

• Dilated cardiomyopathy

Danicopan

Danicopan, also known as ALXN2040 or ACH-0144471, is an investigational drug being studied in clinical trials for the treatment of rare blood and kidney disorders. This article summarizes key information about ongoing and completed clinical trials evaluating danicopan’s safety, efficacy, and pharmacokinetics in conditions like paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy.

Related diseases and areas:

• Paroxysmal nocturnal haemog…
• Dry age-related macular deg…
• Chronic spontaneous urticaria

Dantrolene Sodium

Dantrolene Sodium, a muscle relaxant with unique properties, is being investigated in various clinical trials for its potential benefits beyond its traditional use. These trials explore its efficacy in treating rare genetic disorders, managing critical conditions like heat stroke and cerebral vasospasm, and even addressing ventricular arrhythmias. This article delves into the ongoing research, highlighting the diverse applications of Dantrolene Sodium in medical science.

Related diseases and areas:

• Keratosis follicular
• Skin wrinkling

Dapagliflozin Propanediol

This article examines the use of Dapagliflozin Propanediol, a medication known as an SGLT2 inhibitor, in various clinical trials. These studies investigate its effects on heart conditions, kidney function, and diabetes management. The trials cover a range of doses and patient populations, providing insights into the drug’s potential benefits and safety profile across different medical conditions.

Related diseases and areas:

• Anaplastic large cell lymph…
• Atrial fibrillation
• T-cell lymphoma
• Heart failure with reduced …
• Cardiac failure
• Chronic kidney disease

Dapagliflozin Propanediol Monohydrate

This article explores the use of Dapagliflozin Propanediol Monohydrate in clinical trials, specifically focusing on its potential benefits for patients with acute heart failure. The drug, known commercially as Dapagliflozin, is being studied in a multicenter, randomized, double-blind trial to assess its effects when initiated during hospitalization for acute heart failure. The research aims to determine if early administration of Dapagliflozin can improve cardiovascular outcomes and reduce the risk of worsening heart failure in stabilized patients.

Related diseases and areas:

• Cardiac failure acute

Dapansutrile

Dapansutrile is an investigational drug being studied in clinical trials for its potential to treat a variety of medical conditions. This article explores the ongoing research into dapansutrile’s safety and effectiveness for diseases like gout, heart failure, diabetes, and COVID-19. We’ll examine how this drug works and what the latest clinical trials are revealing about its therapeutic potential.

Related diseases and areas:

• Type 2 diabetes mellitus
• Gout

DAPIGLUTIDE

Dapiglutide is an innovative medication currently being investigated in clinical trials for weight management in people with obesity and overweight. This novel drug works as a dual agonist, targeting both Glucagon-like peptide-1 receptor (GLP-1R) and Glucagon-like peptide-2 receptor (GLP-2R). The DREAM trial (Dapiglutide for the Treatment of Obesity) is exploring how different doses of dapiglutide, administered once weekly via subcutaneous injection, compare to placebo in promoting weight loss over 12 weeks. Another study is examining the pharmacokinetics of different concentrations of the drug. These clinical trials represent important steps in understanding dapiglutide’s potential as a new treatment option for those struggling with obesity.

Related diseases and areas:

• Obesity

Daplusiran

This article explores an ongoing clinical trial investigating the use of Daplusiran/Tomligisiran (DAP/TOM) followed by Bepirovirsen in treating chronic hepatitis B (CHB). The study aims to assess the safety and effectiveness of this sequential therapy in patients already receiving standard nucleos(t)ide analogue (NA) treatment. The trial’s primary goal is to determine the optimal dosage of DAP/TOM when used in combination with Bepirovirsen and to evaluate its contribution to the overall treatment regimen.

Related diseases and areas:

• Hepatitis B
• Hepatitis D

Daratumumab

Daratumumab, a monoclonal antibody targeting CD38, is being extensively studied in clinical trials for its efficacy and safety in treating multiple myeloma and other conditions. These trials aim to evaluate different dosing schedules, administration methods, and combinations with other therapies to optimize treatment outcomes for patients. The research spans various phases and includes healthy volunteers as well as patients with different stages of multiple myeloma.

Related diseases and areas:

• Plasma cell myeloma refractory
• Acute myeloid leukaemia
• Plasma cell myeloma
• Colorectal cancer
• Chronic fatigue syndrome
• Myelodysplastic syndrome

Darbepoetin Alfa

Darbepoetin alfa, also known by the brand name Aranesp, is a medication being studied in clinical trials for treating anemia associated with various medical conditions. These trials are investigating its effectiveness and safety in patients with chronic kidney disease, cancer, myelodysplastic syndromes, and other conditions that can cause anemia. The studies are looking at different dosing regimens and comparing darbepoetin alfa to other anemia treatments to determine the optimal use of this drug.

Related diseases and areas:

• Ischaemic stroke
• Nephrogenic anaemia
• Anaemia of chronic disease

Darunavir

Darunavir is an important antiretroviral medication used in the treatment of HIV infections. This article examines several clinical trials that have investigated the safety, efficacy, and optimal dosing of darunavir in combination with other HIV medications. These studies aim to improve treatment outcomes for patients living with HIV by evaluating different dosing regimens, assessing long-term safety, and optimizing therapy based on patient-specific factors.

Related diseases and areas:

• HIV infection

Dasatinib

Dasatinib is an oral tyrosine kinase inhibitor that has shown promise in treating various types of cancer. This article summarizes key findings from clinical trials investigating the use of dasatinib in conditions such as chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), prostate cancer, breast cancer, and other solid tumors. We’ll explore its efficacy, safety profile, and potential as a treatment option for patients with these challenging diseases.

Related diseases and areas:

• Asymptomatic HIV infection
• Philadelphia chromosome pos…
• Dementia Alzheimer’s type
• HIV infection
• Osteopenia
• Osteoporosis

Dasiglucagon

Dasiglucagon is an innovative drug being studied in clinical trials for its potential to treat hypoglycemia (low blood sugar) in people with diabetes and congenital hyperinsulinism. This article summarizes key findings from recent clinical trials evaluating dasiglucagon’s safety and effectiveness compared to existing treatments. The trials suggest dasiglucagon may offer advantages in raising blood sugar levels quickly and conveniently in emergency situations.

Related diseases and areas:

• Hyperinsulinism

Datopotamab Deruxtecan

Datopotamab Deruxtecan (Dato-DXd) is an innovative antibody-drug conjugate being studied in clinical trials for various advanced cancers, particularly non-small cell lung cancer (NSCLC) and breast cancer. This article explores the ongoing research into Dato-DXd’s efficacy and safety as a potential treatment option for patients with limited alternatives.

Related diseases and areas:

• Bladder cancer
• Neoplasm malignant
• Transitional cell carcinoma
• Breast cancer metastatic
• Hormone refractory breast c…
• Non-small cell lung cancer …

Daunorubicin

Daunorubicin is an important chemotherapy drug being studied in clinical trials for the treatment of acute myeloid leukemia (AML). These trials are exploring how daunorubicin can be combined with other drugs or used in new formulations to improve outcomes for AML patients, especially older adults who often have poorer prognoses. The research aims to find more effective and safer ways to use daunorubicin in treating this aggressive blood cancer.

Related diseases and areas:

• Acute lymphocytic leukaemia
• Acute myeloid leukaemia
• T-cell type acute leukaemia
• Myeloid leukaemia
• Non-Hodgkin’s lymphoma

Davutamig

Davutamig, also known as REGN5093, is an investigational drug being studied for the treatment of advanced non-small cell lung cancer (NSCLC) with MET alterations. This article explores the ongoing clinical trials evaluating the safety, effectiveness, and potential benefits of Davutamig for patients who have exhausted other available treatment options.

Related diseases and areas:

• Non-small cell lung cancer

Daxdilimab

Daxdilimab, also known as HZN-7734, is an investigational drug being studied in clinical trials for various autoimmune conditions. These trials aim to evaluate the efficacy and safety of daxdilimab in treating diseases such as discoid lupus erythematosus, lupus nephritis, and idiopathic inflammatory myositis. The studies involve administering the drug subcutaneously and comparing its effects to a placebo in reducing disease activity and improving patients’ quality of life.

Related diseases and areas:

• Chronic cutaneous lupus ery…
• Dermatomyositis
• Idiopathic inflammatory myo…
• Antisynthetase syndrome

Dazostinag

Dazostinag, a novel drug under investigation, is currently being studied in clinical trials for the treatment of advanced or metastatic solid tumors. This article explores the ongoing research on Dazostinag, both as a single agent and in combination with other therapies, to evaluate its safety, efficacy, and potential benefits for cancer patients.

Related diseases and areas:

• Neoplasm malignant

Dazucorilant

Dazucorilant, also known as CORT113176, is a drug currently being investigated in clinical trials for its potential benefits in treating Amyotrophic Lateral Sclerosis (ALS) and its pharmacokinetic properties. This article explores two ongoing studies: one examining the drug’s interaction with itraconazole in healthy adults, and another evaluating its safety and efficacy in patients with ALS. These trials aim to provide valuable insights into Dazucorilant’s potential as a treatment option and its behavior in the human body.

Related diseases and areas:

• Amyotrophic lateral sclerosis

Dazukibart

Dazukibart is an innovative drug being studied for the treatment of idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM). These conditions cause muscle inflammation and weakness, significantly impacting patients’ quality of life. This article explores the ongoing clinical trials of Dazukibart, its potential benefits, and what patients can expect from this new treatment option.

Related diseases and areas:

• Polymyositis
• Idiopathic inflammatory myo…
• Dermatomyositis

Db-1303

DB-1303/BNT323 is an investigational drug currently being studied in clinical trials for the treatment of advanced breast cancer and endometrial cancer. These trials aim to compare the efficacy and safety of DB-1303/BNT323 with existing treatments in patients who have already undergone previous therapies. The studies focus on specific patient populations, including those with HER2-positive breast cancer, HER2-low hormone receptor-positive breast cancer, and recurrent endometrial cancer.

Related diseases and areas:

• Endometrial cancer
• Hormone receptor positive H…
• Breast cancer
• HER2 negative breast cancer
• Hormone receptor positive b…
• Endometrial cancer recurrent

Dc-806

DC-806 is an investigational drug currently being studied in clinical trials for its potential in treating plaque psoriasis and other conditions. These trials aim to evaluate the drug’s safety, effectiveness, and how it interacts with the body. Researchers are conducting various studies to understand how DC-806 works, its effects on healthy individuals and patients with psoriasis, and how it may interact with other medications.

Related diseases and areas:

• Psoriasis

DCC-3084

DCC-3084 is an investigational drug currently being studied in clinical trials for patients with advanced cancers that are driven by the MAPK pathway. This multicenter, Phase 1/2 clinical trial is evaluating DCC-3084 both as a standalone treatment and in combination with other cancer therapies. The study primarily focuses on patients with advanced or metastatic solid tumors, with a particular interest in specific cancer types including non-small cell lung cancer, pancreatic ductal adenocarcinoma, melanoma, and castration-resistant prostate cancer. The trial is especially targeted at cancers with specific genetic mutations, such as BRAF, CRAF, RAS, and NF1 mutations, which affect the MAPK pathway that regulates cell growth and division.

Related diseases and areas:

• Neoplasm

Dcc-3116

DCC-3116 is an innovative drug currently being studied in clinical trials for its potential in treating various advanced cancers. These trials aim to evaluate the safety and effectiveness of DCC-3116 when used alone or in combination with other anticancer therapies. The studies focus on patients with solid tumors, particularly those with mutations in the RAS/MAPK pathway, and explore different dosing strategies to determine the optimal treatment approach.

Related diseases and areas:

• Non-small cell lung cancer
• Malignant melanoma
• Colorectal cancer
• Neoplasm
• Gastrointestinal stromal tu…
• Adenocarcinoma pancreas

Ddcart‐Cd19

A new clinical trial is investigating the use of DDCART-CD19, a donor-derived CD19-targeted CAR T-cell therapy, for children and young adults with relapsed acute leukemia. This Phase 2 study aims to evaluate the safety and effectiveness of DDCART-CD19 in patients who have experienced a recurrence of their disease after stem cell transplantation or previous CAR T-cell therapy. The trial focuses on patients aged 6 months to 39 years old and seeks to provide hope for those who have limited treatment options.

Related diseases and areas:

• Acute lymphocytic leukaemia…

Defactinib

Defactinib, also known as VS-6063, is an investigational drug being studied in clinical trials for its potential to treat various types of cancer. As a focal adhesion kinase (FAK) inhibitor, defactinib targets a protein involved in cancer cell growth and survival. This article summarizes key information about ongoing clinical trials evaluating defactinib alone or in combination with other therapies for conditions including ovarian cancer, lung cancer, mesothelioma, and other advanced solid tumors.

Related diseases and areas:

• Non-small cell lung cancer
• Ovarian cancer recurrent

Deferiprone

Deferiprone, an oral iron chelator, has been the subject of numerous clinical trials investigating its efficacy and safety in treating various conditions. These trials have explored its use in iron overload disorders, neurodegenerative diseases, and even HIV infection. This article summarizes key findings from clinical trials using deferiprone, providing insights into its potential therapeutic applications and safety profile.

Related diseases and areas:

• Pelizaeus-Merzbacher disease
• Cerebrovascular accident